What is the appropriate management of angina pectoris?

Management of Angina Pectoris

All patients with stable angina pectoris should receive aspirin 75-300 mg daily, a statin, and a beta-blocker as foundational therapy, with sublingual nitroglycerin for acute symptom relief 1, 2, 3.

Core Pharmacological Strategy

Medications to Prevent MI and Death (Mandatory)

These agents reduce mortality and cardiovascular events and should be initiated in all patients unless contraindicated:

• Aspirin 75-300 mg daily - Reduces vascular events (Level A evidence) 1, 3

  • If aspirin is absolutely contraindicated (active GI bleeding, true allergy), substitute clopidogrel (Level B evidence) 1, 2

• Statin therapy - All patients with coronary disease require statins regardless of baseline cholesterol (Level A evidence) 1, 2

  • High-dose statins for very high-risk patients (>2% annual CV mortality) 2

• Beta-blockers - Particularly critical in post-MI patients (Level A evidence), but recommended for all angina patients (Level B evidence without prior MI) 1, 4, 3

  • Reduce mortality by approximately 30% in post-MI trials 2
  • Critical warning: Never stop beta-blockers abruptly; taper over 4 weeks to avoid rebound ischemia 3

• ACE inhibitors - Mandatory in patients with hypertension, diabetes, heart failure, LV dysfunction, or prior MI with LV dysfunction (Level A evidence) 1, 4, 2

  • Should be considered in all CCS patients at very high cardiovascular risk 5
  • The 2024 ESC guidelines upgraded ACE inhibitors to Class IIa recommendation for very high-risk patients 5

Medications for Symptom Relief

First-line symptomatic treatment:

• Sublingual nitroglycerin - For immediate relief and situational prophylaxis before activities that trigger angina 1, 3

  • If sublingual preparations fail, consider buccal formulations 3

• Beta-blockers - First choice for regular symptomatic control unless contraindicated 1, 4, 2

  • Use the cheapest preparation the patient tolerates that controls symptoms 3

If beta-blockers are contraindicated or cause intolerable side effects:

• Long-acting calcium channel blockers are the preferred substitute 1, 4

  • Non-dihydropyridines (diltiazem or verapamil) can substitute for beta-blockers, but NOT if LV dysfunction is present 4
  • Long-acting dihydropyridines (e.g., amlodipine) are safe and effective 1
  • Avoid short-acting dihydropyridines - they increase adverse cardiac events 1

• Long-acting nitrates - Alternative to calcium channel blockers, but require nitrate-free intervals to avoid tolerance 1, 3

  • Nitrate patches must be used at dosages ≥10 mg and removed for 10-12 hours daily to prevent tolerance 3

If symptoms persist on maximal doses of beta-blocker alone:

Add either long-acting calcium channel blocker OR long-acting nitrate (Level B evidence) 1

Combination therapy caution:

• Beta-blocker + non-dihydropyridine CCB (diltiazem/verapamil) increases risk of bradyarrhythmias and heart failure; use with extreme caution 4
• Beta-blocker + long-acting dihydropyridine CCB is safer for combination therapy 4

Second-Line Agents

If symptoms remain uncontrolled on two drugs at maximal therapeutic doses, evidence-based options become limited 3. Consider referral for revascularization rather than adding a third drug 3.

The 2024 ESC guidelines introduced low-dose colchicine (0.5 mg daily) as a Class IIa recommendation to reduce MI, stroke, and need for revascularization in CCS patients with atherosclerotic CAD 5.

Agents NOT Recommended

• Dipyridamole - Does not prevent MI or death (Level B evidence) 1
• Chelation therapy - Not effective and potentially harmful (Level B evidence) 1, 6
• Immediate-release short-acting dihydropyridine calcium antagonists - Increase adverse cardiac events 1

Essential Risk Factor Management

Mandatory Interventions

• Smoking cessation - Advise all smokers to stop; nicotine patches are safe in CAD patients but use as part of comprehensive strategy 3
• Blood pressure control - Target <130/80 mm Hg; <120/80 mm Hg if ventricular dysfunction present 4
  • Critical caution: Lower BP slowly in CAD patients; avoid diastolic BP <60 mm Hg as this may worsen myocardial ischemia 4
• Lipid management - Measure serum cholesterol in all patients; manage per published guidelines 3
• Diabetes control - Strict glycemic control essential 2
• Weight reduction - If BMI elevated, reduce to normal range 3

When to Refer for Revascularization

Immediate referral indications:

• Symptoms uncontrolled on maximal doses of two antianginal drugs 3
• Patients declining medical therapy whose lifestyle is significantly limited 3
• High-risk features on stress testing 2
• Left main stenosis, three-vessel disease (especially with LV dysfunction), or proximal LAD stenosis 2

Important note: The 2024 ORBITA 2 trial demonstrated that PCI provides significant angina symptom improvement over placebo in patients with objective ischemia who remain symptomatic despite medical therapy 5. While initial conservative management is preferred, revascularization should not be neglected for persistent symptoms.

Hypertensive Patients with Angina

For hypertensive patients with chronic stable angina, the optimal regimen includes 4:

1. Beta-blocker (especially if prior MI)
2. ACE inhibitor or ARB (especially if diabetes or LV dysfunction)
3. Thiazide diuretic
4. Add long-acting dihydropyridine CCB if angina or hypertension remains uncontrolled

Common Pitfalls to Avoid

• Never abruptly discontinue beta-blockers - causes rebound ischemia; always taper over 4 weeks 3
• Avoid nitrate tolerance - ensure 10-12 hour nitrate-free interval daily 1, 3
• Don't combine beta-blocker with non-dihydropyridine CCB unless absolutely necessary due to bradycardia/heart failure risk 4
• Don't lower diastolic BP below 60 mm Hg in CAD patients - may worsen ischemia 4
• Don't use short-acting dihydropyridines - they increase adverse events 1
• Monitor third drug effectiveness - if no benefit, discontinue rather than continuing ineffective polypharmacy 3